Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)


Ardizzoni A., Razis E., Lichinitser M., Yilmaz U., Grigorescu A. C., Morero J. L., ...More

JOURNAL OF THORACIC ONCOLOGY, vol.2, no.8, 2007 (SCI-Expanded) identifier